SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-003425 to Zeo ScientifiX, Inc. (ZEOX)

Zeo ScientifiX, Inc.
Date: March 31, 2025 · CIK: 0001557376 · Accession: 0000000000-25-003425

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-286105

Date
March 31, 2025
Author
Division of
Form
UPLOAD
Company
Zeo ScientifiX, Inc.

Letter

Re: Zeo ScientifiX, Inc. Registration Statement on Form S-1 Filed March 26, 2025 File No. 333-286105 Dear Ian T. Bothwell:

March 31, 2025

Ian T. Bothwell Interim Chief Executive Officer Zeo ScientifiX, Inc. 3321 College Avenue, Suite 246 Davie, FL 33314

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Dale S. Bergman, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 31, 2025

Ian T. Bothwell
Interim Chief Executive Officer
Zeo ScientifiX, Inc.
3321 College Avenue, Suite 246
Davie, FL 33314

 Re: Zeo ScientifiX, Inc.
 Registration Statement on Form S-1
 Filed March 26, 2025
 File No. 333-286105
Dear Ian T. Bothwell:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Doris Stacey Gama at 202-551-3188 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Dale S. Bergman, Esq.
</TEXT>
</DOCUMENT>